Table 2. Animals treated with post-transplant APRIL/BLyS blockade did not develop antibody mediated rejection.
| Group | C4d* | t* | v | i* | g* | ptc | mi | ABMR Banff (n)▲ | ACMR Banff (n) |
|---|---|---|---|---|---|---|---|---|---|
| Tx control (G4) | 0.0±0.01 | 1.0±0.92 | 0±0.0 | 1.3±1.03 | 0.3±0.5 | 0.7±1.2 | 1.0±1.7 | 16.6% (1) | 33.3% (2) |
| Pre-tx APRIL/BLyS blockade (G5) | 1.5±1.21 | 0.0±0.02 | 0.0±0.0 | 0.0±0.03 | 0.8±0.84 | 0.8±0.4 | 1.7±1.0 | 83.3% (5) | 0% (0) |
| Post-tx APRIL/BLyS blockade (G6) | 0.4±0.5 | 0.1±0.42 | 0.0±0.0 | 0.3±0.8 | 0.0±0.04 | 0.1±0.4 | 0.1±0.4 | 0% (0) | 14.3% (1) |
| Pre-/post-tx APRIL/BLyS blockade (G7) | 1.1±0.7 | 0.6±0.5 | 0.0±0.0 | 0.6±0.5 | 0.0±0.04 | 0.7±0.5 | 0.7±0.5 | 57.1% (5) | 0% (0) |
Kidney tissue was evaluated for Banff criteria at 21 days post-transplant. Groups listed in far left column as previously described.
1p<0.01 for C4d in Tx control compared with pre-tx APRIL/BLyS blockade
2p<0.05 for t in Tx control compared with pre-tx APRIL/BLyS blockade post-tx APRIL/BLyS blockade
3p<0.02 for i in Tx control compared with pre-tx APRIL/BLyS blockade
4p<0.02 for g in pre-tx APRIL/BLyS blockade compared with post-tx APRIL/BLyS blockade pre-/post-tx APRIL/BLyS blockade
*ANOVA p<0.02
▲p<0.004